Akito Hata

2.6k total citations
117 papers, 1.7k citations indexed

About

Akito Hata is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Akito Hata has authored 117 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Pulmonary and Respiratory Medicine, 84 papers in Oncology and 13 papers in Cancer Research. Recurrent topics in Akito Hata's work include Lung Cancer Treatments and Mutations (84 papers), Lung Cancer Research Studies (48 papers) and Lung Cancer Diagnosis and Treatment (31 papers). Akito Hata is often cited by papers focused on Lung Cancer Treatments and Mutations (84 papers), Lung Cancer Research Studies (48 papers) and Lung Cancer Diagnosis and Treatment (31 papers). Akito Hata collaborates with scholars based in Japan, United States and Italy. Akito Hata's co-authors include Nobuyuki Katakami, Reiko Kaji, Shiro Fujita, Keisuke Tomii, Yukihiro Imai, Hiroshige Yoshioka, Tadashi Ishida, Akihiro Nishiyama, Jumpei Takeshita and Katsuhiro Masago and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Akito Hata

106 papers receiving 1.6k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Akito Hata	1.4k	1.1k	325	320	111	117	1.7k
Satoru Kitazono	833 0.6×	1.0k 0.9×	252 0.8×	349 1.1×	80 0.7×	92	1.5k
Paola Bordi	798 0.6×	800 0.7×	353 1.1×	413 1.3×	54 0.5×	51	1.2k
Jaromı́r Roubec	1.3k 0.9×	1.3k 1.2×	170 0.5×	574 1.8×	55 0.5×	23	1.7k
Siddhartha Devarakonda	801 0.6×	649 0.6×	488 1.5×	484 1.5×	81 0.7×	56	1.3k
Yasir Y. Elamin	518 0.4×	595 0.6×	164 0.5×	284 0.9×	127 1.1×	68	968
Han Han‐Zhang	710 0.5×	672 0.6×	409 1.3×	389 1.2×	114 1.0×	57	1.1k
Rocco Sacco	877 0.6×	658 0.6×	255 0.8×	392 1.2×	103 0.9×	12	1.2k
Ri-Qiang Liao	905 0.7×	917 0.9×	286 0.9×	314 1.0×	83 0.7×	36	1.4k
Lorenzo D’Ambrosio	777 0.6×	590 0.6×	173 0.5×	337 1.1×	126 1.1×	50	1.2k
Julie Milia	992 0.7×	972 0.9×	267 0.8×	352 1.1×	38 0.3×	23	1.3k

Countries citing papers authored by Akito Hata

Since Specialization

Citations

This map shows the geographic impact of Akito Hata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akito Hata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akito Hata more than expected).

Fields of papers citing papers by Akito Hata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akito Hata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akito Hata. The network helps show where Akito Hata may publish in the future.

Co-authorship network of co-authors of Akito Hata

This figure shows the co-authorship network connecting the top 25 collaborators of Akito Hata. A scholar is included among the top collaborators of Akito Hata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akito Hata. Akito Hata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fujimoto, Daichi, Ryota Shibaki, Keiichi Kimura, et al.. (2025). Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning. Lung Cancer. 199. 108079–108079. 1 indexed citations

Harada, Hideyuki, Akito Hata, Nobuaki Mamesaya, et al.. (2025). Intensity-Modulated Radiotherapy for Locally Advanced Lung Cancer in the Immunotherapy Era: A Prospective Study WJOG12019L. JTO Clinical and Research Reports. 6(6). 100828–100828.

Hata, Akito, Simon Fifer, Kazuo Hasegawa, et al.. (2024). Treatment preferences among Japanese patients and physicians for epidermal growth factor receptor‐mutant non‐small cell lung cancer. Cancer Medicine. 13(1). e6777–e6777. 2 indexed citations

Hirano, Katsuya, et al.. (2024). Continuous immunotherapy beyond progression in clinical practice for small cell lung cancer. Thoracic Cancer. 15(15). 1271–1275. 3 indexed citations

Hata, Akito, Yoshihito Kogure, Masahide Oki, et al.. (2024). Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P+C) for PD-L1 TPS ≥50% locally advanced non-small cell lung cancer (LA-NSCLC): Primary analysis from multicenter single arm phase II study (Evolution trial; WJOG11819L).. Journal of Clinical Oncology. 42(17_suppl). LBA8050–LBA8050.

Hata, Akito, Shunichiro Iwasawa, Yusuke Sasaki, Kosei Tajima, & Yasutaka Chiba. (2024). A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients. Advances in Therapy. 41(9). 3520–3538. 1 indexed citations

Inui, Naoki, Yukihiro Toi, Yasuto Yoneshima, et al.. (2023). Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase. Advances in Therapy. 40(11). 4928–4944. 5 indexed citations

Tachihara, Motoko, Akito Hata, Takaaki Tokito, et al.. (2023). Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L). JTO Clinical and Research Reports. 4(10). 100569–100569.

Akamatsu, Hiroaki, Shunsuke Teraoka, Shinkichi Takamori, et al.. (2022). Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L). Clinical Cancer Research. 28(15). 3207–3213. 22 indexed citations

10.

Imamura, Yoshinori, Kazunori Otsui, Kenta Mori, et al.. (2022). Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial. International Journal of Hematology. 115(4). 499–507. 4 indexed citations

11.

Hamada, Akira, Junichi Soh, Akito Hata, et al.. (2021). Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non–small-cell Lung Cancer: SQUAT trial (WJOG 12119L). Clinical Lung Cancer. 22(6). 596–600. 12 indexed citations

12.

Tsukita, Yoko, Takaya Yamamoto, Hiroshi Mayahara, et al.. (2021). Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective study. Radiotherapy and Oncology. 160. 266–272. 30 indexed citations

13.

Takeuchi, Shinji, Tetsunari Hase, Shinobu Shimizu, et al.. (2019). Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer. Cancer Science. 111(2). 561–570. 28 indexed citations

14.

Tachihara, Motoko, Tatsunori Kiriu, Akito Hata, et al.. (2019). <p>A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy</p>. Cancer Management and Research. Volume 11. 7135–7140. 5 indexed citations

15.

Akamatsu, Hiroaki, Yasuhiro Koh, Yuichi Ozawa, et al.. (2018). Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study. Clinical Lung Cancer. 19(6). e871–e874. 12 indexed citations

16.

Nanjo, Shigeki, Sachiko Arai, Wei Wang, et al.. (2017). MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR -mutant Lung Cancer. Molecular Cancer Therapeutics. 16(3). 506–515. 47 indexed citations

17.

Kaneda, Toshihiko, Hiroshige Yoshioka, Motohiro Tamiya, et al.. (2016). Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer. Annals of Oncology. 27. vi436–vi436. 2 indexed citations

18.

Hata, Akito, Nobuyuki Katakami, Shigeki Nanjo, et al.. (2016). Correlation between programmed death-ligand 1 (PD-L1) expression and T790M status in EGFR-mutant non-small cell lung cancer (NSCLC). Annals of Oncology. 27. vi428–vi428. 1 indexed citations

19.

Tanaka, Kosuke, Toyoaki Hida, Yuko Oya, et al.. (2015). EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma. Journal of Thoracic Oncology. 10(12). 1720–1725. 54 indexed citations

20.

Satouchi, Miyako, Yoshikazu Kotani, Nobuyuki Katakami, et al.. (2010). Randomized Phase II Study of Two Different Schedules of Gemcitabine and Oral S-1 in Chemo-naïve Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(5). 696–701. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact